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Objective:
Utilize existing data on the role of the non-
coding genome to determine possible
functional relationships between microRNAs,
their target genes, and COVID-19.
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Fig. 2: The distance of SNPs from the start position of miRNAs. The start of a miRNA is denoted as 0 b. 
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Methods:
PubMed searches using “SNP” and “COVID-19” revealed X papers on the significance of
specific SNPs on the prognosis of patients with COVID-19. The positions of the collected
SNPs were compared to the positions of human miRNAs from miRBase using the hg38
reference genome. SNPs were assigned to a miRNA if less than 100 kb or 1Mb away from the
start of the miRNA sequence (Figure 1). MiRNA target genes were identified using miRWalk
2.0, miRTarBase, miRecords, and Tarbase V8. These targets were compared across miRNAs












































































































































































































































































































SARS-CoV-2 is a novel coronavirus that is
responsible for COVID-19. The infection
results in a wide range of symptoms affecting
the respiratory and cardiovascular systems
that have been noted to differ across race,
age, and sex. Because of the differing
outcomes of infection between groups, it is
critical that biomarkers are identified to
determine the aggressiveness of the infection
prior to the onset of clinical symptoms.
Single nucleotide polymorphisms (SNPs),
which are genetic variations of a single
nucleotide amongst people, have been
associated with the prognosis of COVID-19
infection. Evidence of SNPs, mostly part of
non-coding genome, having an impact on the
progression and outcome of COVID-19
infections1, suggests that they may be
involved in the regulation of the expression of
genes controlling critical biological functions
of physiological responses to viral infections.
MicroRNAs (miRNAs) are short non-coding
RNAs involved in the post-transcriptional
gene regulation by binding to target mRNA
sequences and effectively silencing gene
expression. They are involved in the
regulation of gene controlling many biological
functions including immune responses.
MiRNAs can be easily detected and
quantified in the blood; therefore they can
works as circulating biomarkers2, including
COVID-19.
HYPOTHESIS
We hypothesized that SNPs from genomic
regions linked to COVID-19 aggressivity
contains microRNAs that can be used as
early biomarkers (through their
expression) for the evolution of the
disease.
Fig 3. In the process of miRNA maturation, 
miRNA sequences go through processing in the 
nucleus and transported in the cytoplasm. From 
there, mature miRNAs can be excreted from the 
cell through exosomes into the extracellular 
environment (serum, plasma, etc.). The 
concentration of miRNAs in these environments 




Final results are pending. Preliminary
results revealed 115 human miRNAs in
close proximity to the studied SNPs with
notable clusters in chromosomes 6 and 19
(Figure 2).
For these miRNAs we are now analyzing
the known target messenger RNAs and
identify common signaling pathway. We
expect to discover an enrichment in
immune related signaling targets.
Conclusions:
The confirmed target genes for the
identified miRNAs will be studied using
available databases to identify their
biological significance and possible relation
to COVID-19. A target gene’s biological
significance and possible relation to
COVID-19 will be defined as having
involvement in lung structure and function,
cardiopulmonary function, immune
response, and cytokine release. In order to
confidently determine whether or not the
miRNAs could serve as potential
biomarkers for the prognosis and severity
of COVID-19 infection, further wet-lab
analysis of the miRNA concentrations in
control, surviving patient, and deceased
patient plasma samples is required. Plasma
samples are key samples for miRNA
analysis because miRNAs can be released
into the bloodstream through exosomes,
where miRNAs can be transported to other
cells as shown by Cortez et al’s diagram8
(Figure 3). A statistically significant
difference between the concentrations of
miRNAs in control, surviving patient, and
deceased patient samples would be
considered evidence to support the
classification of a microRNA as a biomarker
for SARS-CoV-2 infection prognosis.
